Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for mdv 3100 (compound)
Most Correlated Studies
- Transcriptional responses of control and MDV3100 resistant lines to DMSO or MDV3100
- Resistance to anti-androgens in prostate cancer cell lines and xenografts
- Prostate cancer cell lines treated with BET domain inhibitors
- Prostate cancer CWR-R1, LAPC-4, LNCaP and VCAP cells treated with Enzalutamide
- Prostate carcinoma LNCaP cells treated with dihydrotestosterone and enzalutamide
Most Relevant Literature
- Enhanced antitumor efficacy by combining afatinib with MDV3100 in castration-resistant prostate canc…
- Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia.
- Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cel…
- MDV3100: Tritium labeling at high specific activity.
- Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in cast…
Most Relevant Clinical Trials
- Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Met…
- NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiven…
- Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant P…
- Tivozanib + Enzalutamide in Adv Prostate Cancer
